BioCryst Pharmaceuticals Inc. (BCRX)
Summary
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to build its rare-disease pipeline and streamline expenses.
BioCryst Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 202 | $1,516.13 | $1,909.91 | $393.78 | 25.97% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 2 | $19 | $18.91 | -$0.09 | -0.47% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 52 | $549.1 | $488.02 | -$61.08 | -11.12% |
 Farallon Capital Farallon Capital Management LLC | 24,000 | $182,160 | $226,989.6 | $44,829.6 | 24.61% |
| BG Bart Gancher Intech Investment Management LLC | 50,078 | $376,058.98 | $470,232.42 | $94,173.44 | 25.04% |
BioCryst Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SS Steven Seedhouse Raymond James | 20,446.33 | $204,463.28 | $186,787.43 | -$17,675.85 | -8.64% |
 Andrew S. Fein HC Wainwright & Co. | 6,277.97 | $62,779.66 | $57,352.36 | -$5,427.3 | -8.64% |
BioCryst Pharmaceuticals Inc. (BCRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioCryst Pharmaceuticals Inc. ever had a stock split?
BioCryst Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Charles K. Gayer CEO | NASDAQ (NGS) Exchange | 09058V103 CUSIP |
| US Country | 435 Employees | - Last Dividend | - Last Split | 3 Mar 1994 IPO Date |
Overview
BioCryst Pharmaceuticals, Inc. is a pioneering biotechnology company focused on the development of oral small-molecule and protein therapeutics aimed at treating rare diseases. Established in 1986, the company is positioned at the forefront of medical research, utilizing cutting-edge technology and innovative approaches to create treatments that significantly improve patient outcomes. Headquartered in Durham, North Carolina, BioCryst maintains a global presence through strategic collaborations and in-license relationships with various internationally recognized institutions and companies. These partnerships enhance the firm's research capabilities and facilitate the broad distribution of its products, reinforcing its commitment to addressing unmet medical needs worldwide.
Products and Services
- Peramivir Injection (RAPIVAB, RAPIACTA, PERAMIFLU)
This product is an intravenous neuraminidase inhibitor designed for the treatment of acute uncomplicated influenza. By targeting the neuraminidase enzyme, peramivir prevents the release of new virus particles, effectively limiting the spread of the influenza virus within the body. Its intravenous administration ensures rapid delivery and action, offering a significant benefit for patients requiring immediate treatment.
- ORLADEYO (Oral Serine Protease Inhibitor)
ORLADEYO is an innovative treatment for hereditary angioedema, a rare and potentially life-threatening genetic condition. As an oral serine protease inhibitor, ORLADEYO works by inhibiting the activity of specific enzymes involved in the cascade of events that lead to angioedema attacks. This treatment represents a significant advancement in the management of hereditary angioedema, providing patients with a convenient oral medication option.
- BCX10013 (Oral Factor D Inhibitor)
Currently under development, BCX10013 is an oral factor D inhibitor targeting complement-mediated diseases. Factor D is a crucial enzyme in the complement pathway, a part of the immune system that plays a key role in inflammation and cell destruction. By inhibiting factor D, BCX10013 aims to provide a novel treatment option for patients with complement-mediated conditions, showcasing BioCryst's commitment to expanding its portfolio of innovative therapies.
